Damora Therapeutics (DMRA) Cash from Operations (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Cash from Operations came in at 20598000.0 in Q1 2026, down 744.53% YoY from 3195834.73 in Q1 2025, and down 3533.0% on a QoQ basis from 600000.0 in Q4 2025.
Damora Therapeutics (DMRA) Cash from Operations (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Cash from Operations data on file, last reported at 20598000.0 in Q1 2026.
- Quarterly Cash from Operations fell 744.53% year-over-year to 20598000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24859000.0 (down 64.21% YoY) and the FY2025 annual result came in at 6700000.0, up 63.98% from the prior year.
- Cash from Operations declined to 20598000.0 in Q1 2026, from 600000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 600000.0 in Q4 2025 to a low of 20598000.0 in Q1 2026.
- A 5-year average of 7395882.35 and a median of 6797000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2025 — Cash from Operations soared 112.24% — and 2026, when it plunged 744.53%.
- Tracing DMRA's Cash from Operations over 5 years: stood at 11448000.0 in 2022, then dropped by 0.13% to 11463000.0 in 2023, then jumped by 57.25% to 4900000.0 in 2024, then jumped by 112.24% to 600000.0 in 2025, then sank by 3533.0% to 20598000.0 in 2026.
- The last three Cash from Operations figures came in at 20598000.0 (Q1 2026), 600000.0 (Q4 2025), and 2624000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | -21.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.90 Mn |
| Jun 30, 2026 | -21.90 Mn |
| Mar 31, 2026 | -20.60 Mn |
| Mar 31, 2026 | -20.60 Mn |
| Dec 31, 2025 | 600,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Sep 30, 2025 | -2.62 Mn |
| Sep 30, 2025 | -2.62 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Mar 31, 2025 | -2.44 Mn |
| Mar 31, 2025 | -2.44 Mn |
| Dec 31, 2024 | -4.90 Mn |
| Dec 31, 2024 | -4.90 Mn |
| Sep 30, 2024 | -3.70 Mn |
| Sep 30, 2024 | -3.70 Mn |
| Jun 30, 2024 | -4.10 Mn |
| Jun 30, 2024 | -4.10 Mn |
| Mar 31, 2024 | -5.90 Mn |
| Mar 31, 2024 | -5.90 Mn |